175 related articles for article (PubMed ID: 8750366)
1. 5-fluorouracil modulates the toxicity of high dose methotrexate.
White RM
J Clin Pharmacol; 1995 Dec; 35(12):1156-65. PubMed ID: 8750366
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of methotrexate administration following 5-fluorouracil.
White RM
Am J Clin Oncol; 1996 Oct; 19(5):492-9. PubMed ID: 8823478
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
Schwartz GK; Christman K; Saltz L; Casper E; Quan V; Bertino J; Martin DS; Colofiore J; Kelsen D
Cancer; 1996 Nov; 78(9):1988-95. PubMed ID: 8909321
[TBL] [Abstract][Full Text] [Related]
4. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Seiter K; Kemeny N; Martin D; Schneider A; Williams L; Colofiore J; Sawyer R
Cancer; 1993 Mar; 71(5):1875-81. PubMed ID: 8448752
[TBL] [Abstract][Full Text] [Related]
5. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
Petrelli N; Herrera L; Rustum Y; Burke P; Creaven P; Stulc J; Emrich LJ; Mittelman A
J Clin Oncol; 1987 Oct; 5(10):1559-65. PubMed ID: 2443619
[TBL] [Abstract][Full Text] [Related]
7. Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin.
Pronzato P; Vaira F; Vigani A; Losardo P; Bertelli G
Anticancer Res; 1995; 15(6B):2679-82. PubMed ID: 8669846
[TBL] [Abstract][Full Text] [Related]
8. [A new sequential chemotherapy of methotrexate with 5-fluorouracil against advanced colo-rectal cancer].
Fujiki T; Futatsuki K; Akazawa S; Yamamoto K; Miyazaki M; Kanda Y; Amemiya K; Uchida N; Oishi T
Gan To Kagaku Ryoho; 1993 Apr; 20(5):603-9. PubMed ID: 8470917
[TBL] [Abstract][Full Text] [Related]
9. Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
Abad A; Garcia P; Gravalos C; Tusquets I; Font A; Perez G; Cortés-Funes H; Fabregat X; Barnadas A; Rosell R
Cancer; 1995 Mar; 75(6):1238-44. PubMed ID: 7882275
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
Valone FH; Friedman MA; Wittlinger PS; Drakes T; Eisenberg PD; Malec M; Hannigan JF; Brown BW
J Clin Oncol; 1989 Oct; 7(10):1427-36. PubMed ID: 2789272
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
[TBL] [Abstract][Full Text] [Related]
12. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
Machiavelli M; Leone BA; Romero A; Rabinovich MG; Vallejo CT; Bianco A; Pérez JE; Rodríguez R; Cuevas MA; Alvarez LA
Am J Clin Oncol; 1991 Jun; 14(3):211-7. PubMed ID: 2031508
[TBL] [Abstract][Full Text] [Related]
13. Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil.
Solan A; Vogl SE; Kaplan BH; Berenzweig M; Richard J; Lanham R
Med Pediatr Oncol; 1982; 10(2):145-9. PubMed ID: 7040929
[TBL] [Abstract][Full Text] [Related]
14. Comparison of methotrexate and sequential methotrexate-5-fluorouracil for patients with recurrent squamous cell carcinoma of the oral cavity.
Airoldi M; Pedani F; Brando V; Gabriele P; Orecchia R
Chemioterapia; 1987 Dec; 6(6):390-2. PubMed ID: 3435920
[TBL] [Abstract][Full Text] [Related]
15. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer.
Marsh JC; Bertino JR; Katz KH; Davis CA; Durivage HJ; Rome LS; Richards F; Capizzi RL; Farber LR; Pasquale DN
J Clin Oncol; 1991 Mar; 9(3):371-80. PubMed ID: 1999706
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
Kelsen DP; Martin D; O'Neil J; Schwartz G; Saltz L; Sung MT; von Borstel R; Bertino J
J Clin Oncol; 1997 Apr; 15(4):1511-7. PubMed ID: 9193347
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
Lokich JJ; Phillips D; Green R; Paul S; Sonneborn H; Zipoli TE; Curt G
Cancer; 1985 Nov; 56(10):2395-8. PubMed ID: 4042072
[TBL] [Abstract][Full Text] [Related]
19. Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity.
Hansen RM; Quebbeman EJ; Ritch PS; Frick J; Anderson T
Am J Clin Oncol; 1987 Jun; 10(3):216-8. PubMed ID: 3496002
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.
Browman GP; Levine MN; Goodyear MD; Russell R; Archibald SD; Jackson BS; Young JE; Basrur V; Johanson C
J Clin Oncol; 1988 Jun; 6(6):963-8. PubMed ID: 3286831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
